Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company
How much larger will the Pharmacogenomics Market be in 2030 compared with 2026?
The pharmacogenomics market has seen significant expansion in recent years. This market is set to increase from $9.84 billion in 2025 to $10.85 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.3%. Key drivers for its historical growth include heightened genomic research activities, the broadening of targeted therapy development, the increasing incidence of chronic diseases, advancements in sequencing technologies, and the rising accessibility of genetic testing services.
The pharmacogenomics market size is anticipated to undergo significant growth in the coming years. It is forecast to reach $15.98 billion in 2030, growing at a compound annual growth rate (CAGR) of 10.2%. This projected expansion during the forecast period stems from factors such as increasing investments in precision medicine programs, the rising adoption of AI-driven genomic analysis, the expansion of pharmacogenomics into oncology and cardiology, a growing emphasis on individualized drug development, and continuous advancements in bioinformatics platforms. Key trends expected in this period include the increasing uptake of personalized medicine approaches, a rising reliance on genetic testing for drug selection, growing integration of pharmacogenomic data within clinical workflows, the expansion of companion diagnostics, and an enhanced focus on precision therapeutics.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7072&type=smp
What Drivers Are Guiding Growth Patterns In The Pharmacogenomics Market?
The escalating prevalence of chronic diseases is anticipated to boost the expansion of the pharmacogenomics market in the coming years. These conditions are defined as long-term health issues that frequently last throughout an individual’s life. The rise in chronic illnesses stems from an extended global average life expectancy alongside the widespread engagement in lifestyle risk factors such as inactivity, unhealthy eating, and tobacco use. Pharmacogenomics provides a tailored method for managing chronic diseases by considering unique genetic differences influencing how individuals react to medication. To illustrate, the International Diabetes Federation, a Belgium-based health organization, reported that in 2024, approximately 589 million adults between 20-79 years old were living with diabetes, with this figure expected to climb to 853 million by 2050; notably, in 2025, over 4 in 5 adults with diabetes reside in low and middle income countries. Consequently, the growing number of chronic diseases is fueling the development of the pharmacogenomics market.
How Is The Pharmacogenomics Market Divided Into Segments?
The pharmacogenomics market covered in this report is segmented –
1) By Technology: Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies
2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, Other Applications
3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, Other End Users
Subsegments:
1) By Next Generation Sequencing (NGS): Whole Genome Sequencing, Targeted Sequencing, Exome Sequencing
2) By Polymerase Chain Reaction (PCR): Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR
3) By Gel Electrophoresis: Agarose Gel Electrophoresis, Polyacrylamide Gel Electrophoresis, Capillary Gel Electrophoresis
4) By Mass Spectrometry: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry), MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight), HRMS (High-Resolution Mass Spectrometry)
5) By Microarray: SNP Microarrays, Expression Microarrays, Comparative Genomic Hybridization (CGH) Arrays
6) By Other Technologies: Sanger Sequencing, CRISPR-Based Technologies, Bioinformatics Tools
Which Competitive Trends Are Impacting The Structure Of The Pharmacogenomics Market?
Leading entities within the pharmacogenomics market are progressively prioritizing AI-powered systems designed to handle drug-drug interactions at the genomic scale, which enhances medication safety, diminishes adverse reactions, and facilitates highly tailored prescribing. These AI-powered pharmacogenetics engines are sophisticated digital platforms employing artificial intelligence to examine an individual’s genetic makeup and forecast their reactions to particular drugs. An illustrative case occurred in December 2024 when PGxAI, a pharmacogenetics firm based in the US and powered by AI, unveiled its Sirius model. This AI-driven pharmacogenetics engine customizes drug selection, dosing, and the handling of drug-drug interactions, all informed by a person’s genome. The Sirius model encompasses 730 drugs and 40 key pharmacogenes, providing significantly wider coverage compared to conventional pharmacogenomic offerings. Intended for utilization by hospital systems, diagnostic laboratories, and clinical research organizations, the model aims to lessen adverse reactions and elevate therapeutic results.
Which Leading Companies Dominate The Pharmacogenomics Market Share?
Major companies operating in the pharmacogenomics market are Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, PerkinElmer Inc, Centogene N.V, Invitae Corporation, Genomind, Pacific Biosciences of California Inc, Oneome LLC, Admera Health, MapMyGenome, Positive Bioscience, Xcode Life Sciences, Takeda Pharmaceutical Company Limited, Garvan Institute of Medical Research, 3D Medicines Inc, Berry Genomics, BGI, GenomiCare Biotechnology, F Hoffmann-La Roche AG, Merck KGaA, QIAGEN N.V, Centro de Genoma e Biologia de Sistemas, Datar Cancer Genetics Limited, MedGenome Labs, 23andMe, Color Genomics, Pathway Genomics, Genomika Diagnósticos
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/pharmacogenomics-global-market-report
Which Region Is Anticipated To See The Fastest Growth In The Pharmacogenomics Market?
North America was the largest region in the pharmacogenomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Pharmacogenomics Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=7072&type=smp
Browse Through More Reports Similar to the Global Pharmacogenomics Market 2026, By The Business Research Company
Pharma 4 0 Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/pharma-4-0-global-market-report
Consumer Genomics Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/consumer-genomics-global-market-report
Pharmaceutical Label Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/pharmaceutical-label-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company